Acquisitions and Divestitures - Additional Information (Detail) In Millions, except Share data, unless otherwise specified	3 Months Ended	6 Months Ended				1 Months Ended	3 Months Ended	6 Months Ended	12 Months Ended
	Jun. 30, 2013 USD ($)	Jun. 30, 2013 USD ($)	Dec. 31, 2012 USD ($)	Jun. 30, 2013 Uteron Pharma, SA [Member] USD ($)	Jan. 23, 2013 Uteron Pharma, SA [Member] USD ($)	Mar. 28, 2013 Actavis Group [Member] USD ($)	Mar. 31, 2013 Actavis Group [Member] USD ($)	Jun. 30, 2013 Actavis Group [Member] USD ($)	Dec. 31, 2012 Actavis Group [Member] USD ($)	Oct. 31, 2012 Actavis Group [Member] USD ($)	Oct. 31, 2012 Actavis Group [Member] EUR (€)	Oct. 31, 2012 Actavis Group [Member] Maximum [Member]	Oct. 31, 2012 Actavis Group [Member] Minimum [Member]
Business Acquisition [Line Items]
Cash consideration					$ 142.0					$ 5,469.8	€ 4,219.7
Potential milestone payments					155.0
Assumption of debt and other liabilities					7.7
Discount rate used to present value product right intangible assets					22.00%							11.50%	8.80%
Contingent consideration				43.4	43.4
Maximum number of shares issuable for contingent consideration										5,500,000	5,500,000
Newly issued shares of Common Stock, par value	$ 0.0033	$ 0.0033	$ 0.0033							$ 0.0033
Step-up in the value of inventories								137.3
Amortization of inventory step -up to cost of sales							93.5		44.1
Estimated weighted average useful life of intangible assets acquired								8 years 8 months 12 days
Weighted average number of shares, contingently issuable	3,850,000	3,850,000				1,650,000			3,850,000
Contingent consideration expense						$ 150.3